Table 4 Demographic and clinical characteristics of patients with idiopathic pulmonary fibrosis receiving pirfenidone
N available | Total | |
|---|---|---|
Gender (male/female), n (%) | 231 | 184 (79.7)/ 47 (20.3) |
Age mean years (SD) | 231 | 68.9 (8.4) |
Smoking habits, n (%) | 231 | |
Never-smoker | 59 (25.9) | |
Ex-smoker | 156 (68.4) | |
Smoker | 13 (5.7) | |
Time from diagnosis to inclusion in the registry, mean years (SD) | 231 | 1.7 (2.1) |
Disease progression since onset of symptoms, mean months (SD) | 211 | 22.7 (23.7) |
Time of treatment with pirfenidone, mean years (SD) | 231 | 1.5 (1.1) |
FVC, mean % of predicted (SD) | ||
At baseline | 226 | 74.1 (15.5) |
After 12 months of treatment | 181 | 71.5 (16.7) |
DLCO, mean % of predicted (SD) | ||
At baseline | 200 | 47.4 (16.9) |
After 12 months of treatment | 150 | 47.2 (17.6) |
6-min walk distance mean m (SD) | ||
At baseline | 158 | 425.5 (114.7) |
After 12 months of treatment | 55 | 429.0 (117.4) |
Diagnostic procedures, n (%) | 231 | |
High-resolution computed tomography | 229 (99.6) | |
Pulmonary function test | 228 (98.7) | |
Autoimmune serology | 213 (94.2) | |
6-min walk test | 173 (77.2) | |
Surgical lung biopsy | 78 (34.2) | |
Lung cryobiopsy | 14 (6.4) | |
Adverse events related to pirfenidone, n (%) | 231 | 54 (23.4) |
Gastrointestinal discomfort | 22 (9.5) | |
Anorexia/weight loss | 18 (7.8) | |
Photosensitivity | 13 (5.6) | |
Fatigue | 10 (4.3) | |
Dizziness | 3 (1.3) | |
Alteration of liver enzymes | 2 (0.9) | |
Others | 9 (3.9) | |